GE HealthCare
GEHC Nasdaq· Health Care Equipment
Last close · Oct 27, 2026
$71.11
KIRA · Stoqly’s AI analyst, in plain words
- GE HealthCare had $20.6B of revenue in fiscal 2025, up 4.8% on the year before.
- Its operating margin was 13.4%, up 0.1 pts: of every 100 in sales, about 13 is left after running the business.
- GE HealthCare made $2.1B of net profit in fiscal 2025. From fiscal 2021 to 2025, diluted EPS grew −2.1% a year.
- Free cash flow was $1.5B in fiscal 2025, 7.3% of revenue.
- GE HealthCare returned $264M to shareholders in fiscal 2025, 18% of free cash flow. The diluted share count fell 0.2%.
- GE HealthCare owes $6.0B more than it holds in cash, about 1.8 years of operating profit.
Market cap
$32.5B
P/E
17.0x
Revenue
$20.6B
Net income
$2.1B
Free cash flow
$1.5B
Operating margin
13.4%
GE HealthCare in 30 seconds · fiscal 2025
Are sales growing?
+4.8%
Only a little. Sales grew 4.8% last year.
Does it make a profit?
10.1%
Yes. It keeps 10.1% of every sale as profit.
Does profit turn into cash?
7.3%
Partly. 7.3% of sales ends up as free cash.
Is debt under control?
1.8x
Keep an eye on it. Repaying its debt would take 1.8 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
17.0x
One share costs 17.0 times its yearly profit per share. Typical for its sector: 28.4x.
What GE HealthCare does
GE HealthCare makes medical imaging machines, patient monitors and the drugs used in scans, and it sells software and services to go with them. Its customers are hospitals, health systems and researchers in more than 160 countries. Revenue comes from selling devices, consumable products, service contracts and cloud and software products. It was spun off from General Electric in January 2023. It reports four segments. Imaging makes CT, MR, X-ray, molecular imaging and women's health scanners. Advanced Visualization Solutions makes ultrasound systems and equipment used in heart procedures and surgery. Patient Care Solutions makes monitors, heart-test (ECG) devices, anesthesia machines and equipment for newborns, with recurring sales of supplies and services. Pharmaceutical Diagnostics supplies contrast media and radioactive tracers that make tissues show up in scans.
Biggest risks, in its own words
- Strong competition that could force price cuts or cost it market share.
- Delays or failures in getting regulatory approval for its products, and strict rules from the FDA and other agencies.
- Health insurers and public payers limiting what they pay, which could reduce prices and demand.
- Supply chain problems that limit its ability to get parts and materials and make its products.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 4, 2026
- Legal name
- GE HEALTHCARE TECHNOLOGIES INC.
- CIK
- 0001932393
GE HealthCare · GEHC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B |
| Revenue growth | — | 4.3% | 6.6% | 0.6% | 4.8% |
| Gross margin | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% |
| Operating margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% |
| Net income | $2.2B | $1.9B | $1.6B | $2.0B | $2.1B |
| Net margin | 12.8% | 10.5% | 8.0% | 10.1% | 10.1% |
| Diluted EPS | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 |
| Cash | |||||
| Cash from operations | $1.6B | $2.1B | $2.1B | $2.0B | $2.0B |
| Capital expenditure | $248M | $310M | $387M | $401M | $482M |
| Free cash flow | $1.4B | $1.8B | $1.7B | $1.6B | $1.5B |
| FCF margin | 7.7% | 9.9% | 8.8% | 7.9% | 7.3% |
| Dividends paid | $0.0M | $0.0M | $41.0M | $55.0M | $64.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $200M |
| Share count change | — | 0.0% | 0.9% | 0.2% | −0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $561M | $1.4B | $2.5B | $2.9B | $4.5B |
| Debt incl. finance leases | — | $8.3B | $10.4B | $10.5B | $10.5B |
| Shareholders' equity | $16.7B | $9.4B | $7.1B | $8.4B | $10.4B |
| Net debt / EBITDA | — | 2.2x | 2.6x | 2.4x | 1.8x |
| Current ratio | — | 1.2x | 1.1x | 1.0x | 1.4x |
| Interest coverage | 69.9x | 32.8x | 4.5x | 5.2x | 6.3x |
| Returns and quality | |||||
| Return on capital | — | — | 10.7% | 13.4% | 13.3% |
| Return on equity | — | — | 19.0% | 25.6% | 22.1% |
| Piotroski F-score | — | — | — | 5 | 7 |
| Altman Z'' | — | 1.4 | 1.0 | 1.3 | 2.0 |
Insiders bought, 12 months
$6.4M
8 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GE HealthCare · GEHC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| GE HealthCare GEHC | $32.5B | 4.8% | 13.4% | 7.3% | 13.3% | 17.0x | 7 |
| Boston Scientific BSX | $66.5B | 19.9% | 18.0% | 18.2% | 9.6% | 18.2x | 7 |
| Becton Dickinson BDX | $53.7B | 8.2% | 11.8% | 12.2% | 5.5% | 58.7x | 6 |
| Stryker SYK | $116.3B | 11.2% | 19.5% | 17.1% | 11.3% | 31.2x | 6 |
| Medtronic MDT | $120.7B | 8.4% | 17.8% | 14.9% | 7.7% | 23.1x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $71.11 a share, the company is worth $32.5B: 17.0 times its earnings of the last four quarters.
GE HealthCare grew sales faster than 0 of its 4 similar companies. Its P/E is higher than 0 of 4.
Source: SEC EDGAR XBRL filings (CIK 0001932393). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.